- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Adriaan Voors on Possible Unexplained Benefits of SGLT2 Inhibitors
Adriaan Voors, MD, University Medical Center Groningen, the Netherlands, discusses how and why sodium-glucose co-transporter 2 (SGLT2) inhibitors act so quickly for patients with heart failure.
Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, discusses how and why sodium-glucose co-transporter 2 (SGLT2) inhibitors act so quickly for patients with heart failure.
Transcript
Can you explain why SGLT2 inhibitors work so quickly?
On the one hand, yes, they work quickly. As you can see in the chronic trials, the survival curves separate really from early on. If I’m honest, with the survival curves that we’ve seen with traditional end points, the time to death and heart failure event, which were nonprespecified end points, were significantly reduced. If you look at the Kaplan Meier curves, they separate only after 15 days, and if it were only the diuretic effects, I would have expected it to be more prevalent already in hospital to get a more early separation of the curves.
Now, we haven’t looked at the quality of life over time. We will have secondary manuscripts; that’s one of the very important ones we will be currently looking at. So it might be that improvement in the symptoms might be early on, but in the heart clinical endpoints like death or hospital readmission, the curves separate only after 15 days—so that may be indicating something else is going on with these drugs as well, besides decongestant and diuresis.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
